Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Servier
Servier
Eli Lilly and Company
Instituto do Cancer do Estado de São Paulo
National Cancer Institute (NCI)
Turning Point Therapeutics, Inc.
Sotio Biotech Inc.
Pfizer
Pfizer
M.D. Anderson Cancer Center
Stanford University
Erasca, Inc.
Sichuan Enray Pharmaceutical Sciences Company
Arvinas Inc.
University of Colorado, Denver
Eli Lilly and Company
RenJi Hospital
Degron Therapeutics Co.
Bayer
Actym Therapeutics, Inc.
Merck Sharp & Dohme LLC
Ikena Oncology
Eli Lilly and Company
Washington University School of Medicine
Sensei Biotherapeutics, Inc.
Jonsson Comprehensive Cancer Center
Sichuan Enray Pharmaceutical Sciences Company
Apollomics Inc.
ModeX Therapeutics, An OPKO Health Company
TransThera Sciences (Nanjing), Inc.
Hoffmann-La Roche
Columbia University
Eli Lilly and Company
Theratechnologies
Xynomic Pharmaceuticals, Inc.
SOLTI Breast Cancer Research Group
Cedars-Sinai Medical Center
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
Salubris Biotherapeutics Inc
NantCell, Inc.
Turning Point Therapeutics, Inc.
ABM Therapeutics Corporation
TransThera Sciences (Nanjing), Inc.
Istituti Clinici Scientifici Maugeri SpA
M.D. Anderson Cancer Center
Hoffmann-La Roche
Genmab
Kineta Inc.
Institut Bergonié
Blue Note Therapeutics